Even in such rare diseases, understanding and manipulating PIEZO1 could generate considerable benefits for conditions that currently have limited treatment options, but, it is our hypothesis, that the benefits of targeting PIEZO1 will extend beyond these conditions and may include conditions that involve PIEZO1 but are not necessarily caused or exacerbated by PIEZO1 variation such as secondary lymphedema arising from factors such as obesity, inflammation, fibrosis and physical injury [157]. This evidence concerns the gene PIEZO1 and lymphedema.